GO:0030116 glial cell-derived neurotrophic factor receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030116 describes the molecular function of a growth factor binding selectively and non-covalently to glial cell-derived neurotrophic factor (GDNF) family receptors.
• The GDNF family ligands (GDNF, neurturin, artemin, persephin) signal through the GPI-anchored co-receptor GFRα and the RET receptor tyrosine kinase.
• GFRAL is the receptor for GDF15, a distant member of the GDNF family, and mediates metabolic and anti-obesity effects.
• GDNF signaling via ALK5/Smad contributes to hepatic stellate cell activation and liver fibrosis.
• GDNF can inhibit mast-cell-like RBL-2H3 cell activation through Ca2+-mediated degranulation and the Ca2+/CaMKII/JNK pathway.
• Cancer-associated fibroblasts ectopically expressing GDF15 enhance melanoma immunosuppression via the GFRAL/RET cascade.
Description
GO:0030116, glial cell-derived neurotrophic factor receptor binding, is a molecular function term that captures the selective, non-covalent interaction between a growth factor ligand and a glial cell-derived neurotrophic factor (GDNF) family receptor. This function is central to neurotrophic signaling, where ligands such as GDNF bind to glycosylphosphatidylinositol (GPI)-anchored GFRα co-receptors and assemble a signaling complex with the RET receptor tyrosine kinase. The term is defined by the ligand-receptor binding event itself, distinguishing it from downstream catalytic activities such as receptor tyrosine kinase activity. Researchers study GO:0030116 to understand how neurotrophic and metabolic signals are initiated at the cell surface and how these events are rewired in disease. Beyond classical neurotrophic actions, ligands acting through GDNF family receptors now include GDF15, which binds GFRAL and regulates food intake and body weight. This expanded ligand-receptor repertoire has broadened the relevance of GO:0030116 from neurobiology to metabolism, immunology, and oncology. Because the binding event is the first committed step in these pathways, it is a prime target for functional interrogation using CRISPR-based models and receptor-binding assays.
glial cell-derived neurotrophic factor receptor binding At A Glance
| GO ID | GO:0030116 |
|---|---|
| GO term | glial cell-derived neurotrophic factor receptor binding |
| Ontology | molecular_function |
| Synonym | glial cell line-derived neurotrophic factor receptor binding; glial cell line-derived neurotrophic factor receptor ligand |
| Major function | Selective, non-covalent binding of a growth factor to GDNF-family receptors, initiating receptor complex assembly and downstream signaling |
| Ligand examples | GDNF, neurturin, artemin, persephin, and GDF15 |
| Receptor examples | GFRα family co-receptors and GFRAL; signaling partner RET |
| Related disease areas | Neurodegeneration, metabolic disorders, liver fibrosis, cancer immunosuppression |
What Is GO:0030116?
GO:0030116 is defined as a growth factor that binds selectively and non-covalently to glial cell-derived neurotrophic factor receptors. In other words, it describes the ligand side of the ligand-receptor interaction: a secreted growth factor molecule that recognizes and physically associates with a GDNF-family receptor without forming covalent bonds. This function is upstream of receptor activation and is required for subsequent intracellular signaling. The term is a molecular function, not a biological process or cellular component, and it is often annotated to ligands such as GDNF and related family members that engage GFRα co-receptors or GFRAL.
Why Is glial cell-derived neurotrophic factor receptor binding Important in Cell Biology?
GO:0030116 matters because the binding of GDNF-family ligands to their receptors is the initiating event for signaling cascades that control neuronal survival, metabolic homeostasis, and immune regulation. Defects or dysregulation of this binding function have been linked to neurodegeneration, obesity, liver fibrosis, and tumor immune evasion. Because the interaction is extracellular and selective, it is also a tractable target for therapeutic antibodies, decoy receptors, and small-molecule modulators. Understanding the precise binding determinants helps researchers interpret genetic variants and design experiments that separate ligand-receptor recognition from downstream kinase activation.
• Defines the first step in GDNF family signaling, enabling assembly of GFRα-RET complexes.
• Underpins neurotrophic support for dopaminergic and other neuronal populations.
• Mediates GDF15-GFRAL binding that suppresses appetite and promotes weight loss.
• Contributes to hepatic stellate cell activation and liver fibrosis through GDNF-ALK5/Smad signaling.
• Modulates mast cell activation and degranulation via Ca2+/CaMKII/JNK pathways.
• Supports tumor immune evasion when GDF15 is expressed by cancer-associated fibroblasts.
• Provides a druggable extracellular interface for blocking or enhancing ligand-receptor engagement.
• Serves as a functional readout for CRISPR screens targeting ligand-receptor interactions.
• Links neurotrophic biology to metabolic and immune disease mechanisms.
• Guides design of binding assays and receptor occupancy studies in translational research.
Molecular Mechanism of glial cell-derived neurotrophic factor receptor binding
Ligand recognition and initial contact
In simple terms: The growth factor first finds and docks onto its receptor on the cell surface.
GDNF family ligands are secreted proteins that selectively recognize GDNF family receptors. The binding is non-covalent and depends on complementary surface features between the ligand and the receptor ectodomain. This initial contact is the defining event of GO:0030116 and is required for all downstream signaling.
Co-receptor engagement and complex assembly
In simple terms: The ligand brings together a co-receptor and a signaling receptor to form a working complex.
GDNF binds to GPI-anchored GFRα co-receptors, and this ligand-GFRα complex recruits and activates the RET receptor tyrosine kinase. The binding function therefore nucleates a multi-protein complex at the membrane. For GDF15, the orphan receptor GFRAL serves as the specific binding partner, and GFRAL is required for the anti-obesity effects of the ligand.
Signaling initiation and downstream cascades
In simple terms: Once the ligand is bound, the receptor switches on signals inside the cell.
Ligand binding to GFRα-RET triggers RET autophosphorylation and downstream pathways that support neuronal survival and other responses. In hepatic stellate cells, GDNF mediates activation via ALK5/Smad signaling, showing that the binding event can feed into non-canonical pathways. In mast-cell-like RBL-2H3 cells, GDNF inhibits activation via Ca2+-mediated degranulation and the Ca2+/CaMKII/JNK pathway.
Pathological rewiring of binding specificity
In simple terms: In disease, the same binding event can be used for harmful signaling.
Cancer-associated fibroblasts ectopically expressing GDF15 enhance melanoma immunosuppression via the GFRAL/RET cascade, illustrating how ligand-receptor binding can be co-opted in the tumor microenvironment. Artemin, another GDNF family member, has been implicated in neurological disorders and cancers, further broadening the disease relevance of this binding function.
Key Genes Involved in GO:0030116 glial cell-derived neurotrophic factor receptor binding
The following genes and proteins are directly or functionally linked to GO:0030116, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GDNF | Prototypical ligand that binds GDNF family receptors | Central to neurotrophic signaling and receptor binding assays |
| GFRAL | Receptor for GDF15 | Mediates metabolic and anti-obesity effects |
| GDF15 | Ligand that binds GFRAL | Links metabolism, cancer immunosuppression, and receptor binding |
| RET | Signaling receptor tyrosine kinase recruited by ligand-GFRα complexes | Transduces GDNF family signals |
| GFRα family | GPI-anchored co-receptors for GDNF family ligands | Essential for ligand binding and complex assembly |
| ALK5 | Mediates GDNF-induced Smad signaling in hepatic stellate cells | Links receptor binding to liver fibrosis |
| CaMKII | Kinase involved in GDNF-mediated mast cell inhibition | Readout of GDNF receptor binding effects |
| JNK | Stress-activated kinase downstream of GDNF in mast cells | Pathway node for functional studies |
| Artemin | GDNF family ligand | Implicated in neurological disorders and cancers |
| Neurturin | GDNF family ligand | Related ligand with shared receptor binding logic |
| Persephin | GDNF family ligand | Related ligand with shared receptor binding logic |
| Smad2/3 | Downstream effectors of ALK5 signaling | Mediates fibrotic responses to GDNF |
| Ca2+ channels | Regulate degranulation in mast cells | Functional context for GDNF receptor binding |
| RBL-2H3 | Mast-cell-like line used to study GDNF effects | Model for degranulation and signaling |
| Cancer-associated fibroblasts | Source of ectopic GDF15 | Tumor microenvironment context for GFRAL/RET signaling |
| Melanoma cells | Target of GDF15-mediated immunosuppression | Disease model for GFRAL/RET cascade |
| Hepatic stellate cells | Respond to GDNF via ALK5/Smad | Model for liver fibrosis |
How Is glial cell-derived neurotrophic factor receptor binding Regulated?
The binding function described by GO:0030116 is regulated at multiple levels. Ligand availability is controlled by expression, secretion, and extracellular processing, while receptor availability depends on GFRα and GFRAL expression and membrane localization. In hepatic stellate cells, GDNF-mediated activation via ALK5/Smad signaling provides a regulatory link between receptor binding and fibrotic gene programs. In mast cells, Ca2+ signaling and Ca2+/CaMKII/JNK pathways modulate the cellular response to GDNF, indicating that downstream kinases can shape the outcome of receptor binding. In cancer, ectopic GDF15 expression in cancer-associated fibroblasts rewires GFRAL/RET signaling to promote immunosuppression, showing that the binding event can be regulated by the tumor microenvironment.
glial cell-derived neurotrophic factor receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GDF15/GFRAL | Obesity and metabolic regulation | Gfral knockout mouse; GDF15 overexpression cell lines |
| GDNF/ALK5 | Liver fibrosis | Hepatic stellate cell activation assays with GDNF treatment |
| GDF15/GFRAL/RET | Melanoma immunosuppression | Cancer-associated fibroblast co-culture with melanoma cells |
| GDNF/GFRα/RET | Neurodegeneration | Neuronal survival assays with GDNF family ligands |
| GDNF/CaMKII/JNK | Mast cell activation and degranulation | RBL-2H3 mast-cell-like degranulation assays |
Neurodegeneration and neurotrophic support
GDNF family ligands are well-established neurotrophic factors, and their binding to GDNF family receptors is required for signaling that supports neuronal survival. Artemin, another family member, has been implicated in neurological disorders, highlighting the broader relevance of this binding function to nervous system disease.
Metabolic disease and obesity
GDF15 binds GFRAL, and this interaction is required for the anti-obesity effects of the ligand in mice and nonhuman primates. The metabolic effects of GDF15 are mediated by GFRAL, making the binding event a key node in energy balance regulation.
Liver fibrosis
GDNF mediates hepatic stellate cell activation via ALK5/Smad signaling, linking GDNF receptor binding to fibrotic responses in the liver. This expands the disease relevance of GO:0030116 beyond the nervous system.
Cancer and immunosuppression
Ectopic expression of GDF15 in cancer-associated fibroblasts enhances melanoma immunosuppression via the GFRAL/RET cascade. This demonstrates that ligand-receptor binding within the tumor microenvironment can promote immune evasion and supports targeting this interaction in cancer research.
From glial cell-derived neurotrophic factor receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of the receptor abolish ligand binding and signaling? | Knockout of GFRAL or GFRα in cell lines |
| Does a specific residue mediate ligand-receptor binding? | Point mutation of the receptor ectodomain |
| Can a tagged receptor be used to track binding and trafficking? | Knock-in of an epitope tag at the endogenous locus |
| Does overexpression of the ligand enhance downstream signaling? | Overexpression of GDNF or GDF15 in target cells |
| Which pathways are activated after receptor binding? | Pathway reporter assays and phospho-kinase profiling |
| Does the ligand-receptor interaction affect immune cell function? | Co-culture of cancer-associated fibroblasts with immune or melanoma cells |
How to Study the glial cell-derived neurotrophic factor receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Ligand-receptor binding affinity and kinetics | Characterizing GDNF family ligand-receptor interactions |
| CRISPR knockout | Loss-of-function of receptor or ligand | Testing requirement for binding and signaling |
| Point mutation | Role of specific residues in binding | Mapping the ligand-receptor interface |
| Phospho-immunoblotting | Activation of RET, Smad, CaMKII, JNK | Downstream signaling after ligand binding |
| Degranulation assay | Mast cell activation | Functional effect of GDNF on RBL-2H3 cells |
| Co-culture assays | Immune suppression in tumor microenvironment | GDF15-GFRAL/RET effects in melanoma |
| Reporter assays | Transcriptional output of Smad or other pathways | Linking binding to gene expression |
| Overexpression | Gain-of-function of ligand or receptor | Modeling ectopic ligand expression in disease |
Receptor binding assays
Direct ligand-receptor binding can be measured using recombinant proteins, surface plasmon resonance, or cell-based binding assays. These methods quantify affinity and specificity of GDNF family ligands for their receptors.
CRISPR knockout and point mutation
CRISPR-Cas9 knockout of receptors such as GFRAL or GFRα, and point mutation of candidate binding residues, allow causal testing of the binding interface. Such models help distinguish binding-dependent from binding-independent effects.
Phospho-signaling and pathway profiling
Downstream activation of RET, ALK5/Smad, CaMKII, and JNK can be monitored by immunoblotting and phospho-kinase arrays after ligand stimulation.
Functional cellular assays
Degranulation assays in RBL-2H3 cells, hepatic stellate cell activation assays, and immune suppression co-cultures provide functional readouts of receptor binding outcomes.
How CRISPR Can Be Used to Study GO:0030116 glial cell-derived neurotrophic factor receptor binding
Knockout
CRISPR knockout of GFRAL, GFRα, or RET can abolish ligand binding and downstream signaling, providing definitive evidence for the requirement of GO:0030116 in a given cellular response.
Point Mutation
Introducing point mutations into the receptor ectodomain or ligand binding surface allows precise mapping of residues that mediate selective, non-covalent binding. This approach is useful for separating binding from activation.
Knock-in
Knock-in of epitope tags or fluorescent reporters at endogenous loci enables tracking of receptor localization, binding, and trafficking without overexpression artifacts.
Overexpression
Overexpression of GDNF or GDF15 in cell lines or cancer-associated fibroblasts can model gain-of-function states observed in disease, such as enhanced GFRAL/RET signaling and immunosuppression.
How EDITGENE Supports glial cell-derived neurotrophic factor receptor binding Research
Researchers studying glial cell-derived neurotrophic factor receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor complex assembly, or downstream signaling. EDITGENE provides CRISPR-based cell models and screening services designed to answer these questions with reproducible, publication-ready data.
Contact EDITGENE today to design your custom CRISPR model for glial cell-derived neurotrophic factor receptor binding research.
Frequently Asked Questions About glial cell-derived neurotrophic factor receptor binding
What is GO:0030116?
GO:0030116 is the molecular function term for glial cell-derived neurotrophic factor receptor binding, defined as a growth factor that binds selectively and non-covalently to GDNF family receptors.
What genes are involved in glial cell-derived neurotrophic factor receptor binding?
Key genes include GDNF, GFRAL, GDF15, RET, and the GFRα co-receptor family, as well as downstream effectors such as ALK5, CaMKII, and JNK.
What is the function of GDNF receptor binding?
It initiates assembly of ligand-GFRα-RET complexes and activates downstream signaling that supports neuronal survival and other cellular responses.
How is GDF15 related to GDNF receptor binding?
GDF15 binds the orphan receptor GFRAL, a distant GDNF family receptor, and this interaction mediates metabolic and anti-obesity effects.
Is glial cell-derived neurotrophic factor receptor binding involved in cancer?
Yes, ectopic GDF15 in cancer-associated fibroblasts enhances melanoma immunosuppression via the GFRAL/RET cascade.
What diseases are linked to GDNF family receptor binding?
Neurodegeneration, obesity and metabolic disorders, liver fibrosis, and cancer immunosuppression have been linked to this binding function.
How can I study glial cell-derived neurotrophic factor receptor binding in the lab?
Common approaches include receptor binding assays, CRISPR knockout or point mutation of receptors, phospho-signaling profiling, and functional cellular assays.
What is the role of RET in GDNF receptor binding?
RET is the receptor tyrosine kinase recruited by ligand-GFRα complexes and is required for transducing GDNF family signals.
Does GDNF affect mast cells?
GDNF can inhibit mast-cell-like RBL-2H3 cell activation via Ca2+-mediated degranulation and the Ca2+/CaMKII/JNK pathway.
What experimental models are used for GO:0030116 research?
Knockout, point mutation, knock-in, and overexpression cell models, as well as co-culture and degranulation assays, are commonly used.
Conclusion
GO:0030116, glial cell-derived neurotrophic factor receptor binding, defines the selective, non-covalent interaction between GDNF family ligands and their receptors. This binding event initiates signaling through GFRα-RET complexes and GFRAL, with broad implications for neuronal survival, metabolism, liver fibrosis, and cancer immunosuppression. Because the interaction is extracellular and selective, it is an attractive target for functional studies and therapeutic intervention. CRISPR-based knockout, point mutation, knock-in, and overexpression models, combined with binding and signaling assays, provide a robust toolkit for dissecting this molecular function in health and disease.
References
- 1. Zhao Z et al.. 2025. Ectopic expression of GDF15 in cancer-associated fibroblasts enhances melanoma immunosuppression via the GFRAL/RET cascade.. J Immunother Cancer 13(6) PMID: 40555562
- 2. Huang W et al.. 2025. Glial cell line-derived neurotrophic factor inhibits mast-cell-like RBL-2H3 cells activation via Ca2+-mediated degranulation and Ca2+/CaMKⅡ/JNK pathway.. Front Pharmacol 16:1697815 PMID: 41341025
- 3. Saarma M et al.. 1999. Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF).. Microsc Res Tech 45(4-5):292-302 PMID: 10383122
- 4. Emmerson PJ et al.. 2017. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.. Nat Med 23(10):1215-1219 PMID: 28846098
- 5. Tao L et al.. 2019. Glial cell line-derived neurotrophic factor (GDNF) mediates hepatic stellate cell activation via ALK5/Smad signalling.. Gut 68(12):2214-2227 PMID: 31171625
- 6. Mullican SE et al.. 2017. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.. Nat Med 23(10):1150-1157 PMID: 28846097
- 7. Yang L et al.. 2017. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand.. Nat Med 23(10):1158-1166 PMID: 28846099
- 8. Zhu S et al.. 2020. The role of glial cell line-derived neurotrophic factor family member artemin in neurological disorders and cancers.. Cell Prolif 53(7):e12860 PMID: 32573073
